ABSTRACT

Introduction Exercise intolerance is common in patients with chronic obstructive pulmonary disease (COPD) and, although multifactorial, it is largely caused by lower-limb muscle dysfunction. Research has shown that patients with severe to very severe COPD have significantly lower levels of muscle carnosine, which acts as a pH buffer and antioxidant. Beta-alanine (BA) supplementation has been shown to consistently elevate muscle carnosine in a variety of populations and may therefore improve exercise tolerance and lower-limb muscle function. The primary objective of the current studies is to assess the beneficial effects of BA supplementation in enhancing exercise tolerance on top of two types of exercise training (non-linear periodised exercise (NLPE) training or neuromuscular electrical stimulation (NMES)) in patients with COPD.

Methods and analysis Two randomised, double-blind, placebo-controlled trials have been designed. Patients will routinely receive either NLPE (BASE-TRAIN trial) or NMES (BASE-ELECTRIC trial) as part of standard exercise-based care during their 8- to 10-week pulmonary rehabilitation (PR) programme. A total of 222 patients with COPD (2×77 = 154 patients in the BASE-TRAIN trial and 2×34 = 68 patients in the BASE-ELECTRIC trial) will be recruited from two specialised PR centres in The Netherlands. For study purposes, patients will receive 3.2 g of oral BA supplementation or placebo per day. Exercise tolerance is the primary outcome, which will be assessed using the endurance shuttle walk test (BASE-TRAIN) or the constant work rate cycle test (BASE-ELECTRIC). Furthermore, quadriiceps muscle strength and endurance, cognitive function, carnosine levels (in muscle), BA levels (in blood and muscle), markers of oxidative stress and inflammation (in blood, muscles and lungs), physical activity and quality of life will be measured.

Strengths and limitations of this study

► Two prospective, randomised, double-blind, placebo-controlled trials are designed and will be performed in two specialised pulmonary rehabilitation centres to assess the effects of oral beta-alanine (BA) supplementation on exercise tolerance and muscle carnosine in patients with chronic obstructive pulmonary disease (COPD).
► These are the first studies in which BA supplementation will be combined with a supervised exercise intervention (non-linear periodised exercise or neuromuscular electrical stimulation as part of pulmonary rehabilitation) in patients with COPD.
► In-depth assessment of outcomes enables to identify relevant factors that explain variances in muscle carnosine loading and to analyse carnosine’s role in skeletal muscle dysfunction in COPD.
► Long-term benefits will not be investigated as limited funding makes it difficult to set up a comprehensive follow-up period in these trials.

INTRODUCTION

Exercise intolerance is one of the key disabling factors in patients with chronic obstructive pulmonary disease (COPD). Although complex and multifactorial, exercise intolerance is largely caused by lower-limb...
muscle dysfunction. Structural and metabolic muscular alterations in patients with COPD lead to a decreased muscle oxidative capacity, which results in early lactate acidosis and contractile fatigue. To date, non-linear periodised exercise (NLPE) training and neuromuscular electrical stimulation (NMES; for the most disabled and dyspnoeic patients) are among the best available strategies to improve exercise tolerance and lower-limb muscle function in COPD. Indeed, muscle strength and endurance improved following 8–12 weeks of exercise training. Improved muscle function was accompanied by increased exercise tolerance, a better quality of life and less symptoms, without a change in lung function. Even though exercise-based interventions, such as NLPE and NMES, significantly improve exercise tolerance in COPD, targeted nutritional modulation should also be considered as a potential ergogenic aid to further enhance their efficacy.

Beta-alanine (BA), a naturally occurring beta amino acid, is a specific nutritional supplement that is mostly used by athletes to increase exercise tolerance. Once ingested, BA combines with histidine to form carnosine, one of the most abundant metabolites in human muscle cells. Carnosine’s main physiological roles in skeletal muscle include its function as a pH buffer and calcium regulator. High concentrations of muscle carnosine appear to delay the onset of contractile fatigue, as carnosine is able to bind muscle hydrogen ions during intense exercise, thereby moderating the decline in intracellular pH and to increase calcium sensitivity in muscle fibres. Moreover, carnosine can serve as an antioxidant by directly interacting with reactive oxygen species (ROS). The muscle homeostasis and contractile function of especially fast-twitch fibres seem to depend on the presence of carnosine, since they contain twice as much carnosine as slow-twitch fibres. It is well known that the proportion of fast-twitch fibres in the quadriceps muscle of patients with COPD is increased in those with more advanced airflow limitation compared with patients with less severe airflow limitation. Therefore, patients with severe COPD intuitively are expected to have the highest muscle carnosine concentrations. Interestingly, patients with a severe degree of airflow limitation had lower muscle carnosine levels compared with healthy controls. This carnosine deficiency may be closely related to exercise-induced oxidative stress in the lower-limb muscles of patients with COPD or with the fact that in these muscle-wasted COPD patients fast-twitch fibre size is significantly decreased.

Oral supplementation of BA, the rate-limiting factor for carnosine synthesis in skeletal muscle, is reported to be safe and can increase muscle carnosine levels by 60%–80% in both healthy young adults and elderly, without exercise training. However, research has shown that trained muscles load carnosine even more efficiently than untrained muscles. Hence, it is very plausible to hypothesise that BA supplementation in patients with COPD receiving either NLPE or NMES training (as part of pulmonary rehabilitation (PR)) will increase muscle carnosine levels, which, in turn, will result in a positive effect on exercise tolerance and lower-limb muscle function, by buffering pH and scavenging ROS. These adaptations may translate into improved functional capacity during activities of daily living and improved quality of life.

The primary targets of both exercise training and BA supplementation are the muscles of ambulation. Nevertheless, it seems reasonable to hypothesise that an enhanced bioavailability of carnosine in the body, by means of BA supplementation, may have an antioxidant effect in both the lungs and the brain. Interestingly, on oral supplementation, carnosine is taken up by the PEPT2 transporter at the lung membrane, resulting in enhanced carnosine levels in lung tissue. Likewise, elevations in carnosine in all compartments of the brain were measured after BA supplementation in rats. These elevations in carnosine increased the resiliency to stress and were inversely associated with anxiety index.

To date, the safety and efficacy of BA supplementation during usual care (not combined with exercise training) in patients with COPD has only been assessed once (NCT02770417). Therefore, we have designed two randomised, double-blind, placebo-controlled trials in which we will assess the beneficial effects of BA supplementation in enhancing exercise tolerance in addition to two types of exercise training (NLPE and NMES) in patients with COPD. This manuscript describes the protocol of the BASE-TRAIN (NLPE) and BASE-ELECTRIC (NMES) study and gives an overview of its strengths, methodological considerations and assumed clinical implications.

METHODS AND ANALYSIS

The BASE-TRAIN study and BASE-ELECTRIC study are designed by the BASES consortium, a multidisciplinary collaboration between CIRO (Horn, The Netherlands), Radboud University Medical Centre Dekkerswald (Nijmegen, The Netherlands), MEREM (Hilversum, The Netherlands), Maastricht University Medical Centre (Maastricht, The Netherlands), Hasselt University (Diepenbeek, Belgium), Ghent University (Ghent, Belgium) and Montpellier University (Montpellier, France). The consortium consists of researchers from organisations with years of experience in various related disciplines. To provide valuable insight from the patient perspective, a patient advisory board, consisting of representatives of both the CIRO client council and Lung Foundation Netherlands, is closely involved by advising and monitoring the BASES consortium.

Study design

Two prospective, randomised, double-blind, placebo-controlled trials enrolling patients with COPD with explicit functional limitations and high symptom burden (GOLD classification B or D) have been designed and
will be performed in Radboud University Medical Centre Dekkerswald (Nijmegen, The Netherlands) and CIRO (Horn, The Netherlands). The expected trial duration is 2 years from first patient in (1 September 2020) to last patient out (1 September 2022). In both trials, the intervention (BA supplementation) will be part of a comprehensive, interdisciplinary PR programme consisting of educational sessions, psychosocial and nutritional counselling, supervised physical exercise training, occupational therapy and COPD exacerbation management, as defined in the latest statement by the American Thoracic Society (ATS) and the European Respiratory Society (ERS).3

Eligible patients are those who satisfy the criteria listed in Table 1. Patients are excluded if they meet at least one of the following criteria: unstable cardiac disease, use of anabolic steroids during PR programme, history of drugs/alcohol abuse, participants treated with NMES (BASE-TRAIN trial) or NLPE (BASE-ELECTRIC trial) during the PR programme, vegetarianism, inability to understand the Dutch language, self-reported BA supplementation in the past 3 months (wash-out period: 9 weeks), participation in a PR programme within the past 12 months, inability to perform an incremental shuttle walk test (BASE-TRAIN trial) or cardiopulmonary exercise test (BASE-ELECTRIC trial). Furthermore, patients with bleeding disorder, a recent trauma of the muscle or an infection in the region of the proposed biopsy will be excluded for the muscle biopsies.30

The regular PR programme at the PR centres consists of a baseline assessment, followed by the (BASE-TRAIN: inpatient or outpatient; BASE-ELECTRIC: inpatient) PR programme and is ended with a post-rehabilitation assessment. After completion of the baseline assessment and obtaining informed consent, an additional study-related appointment is scheduled with included patients approximately 1 week prior to the start of the PR programme. The appointment includes fasting venous blood sampling, a vastus lateralis muscle biopsy (optional, not required), two cognitive function tests (modified Wisconsin Card Sorting Test; M-WCST and Stroop Colour-Word Test; SCWT) and, only in the BASE-ELECTRIC trial, two tests for lung inflammatory biomarkers (volatile organic compounds; VOCs and fractional nitric oxide concentration in exhaled breath; FeNO). This additional testing day will be repeated after the rehabilitation period. The total study duration per subject will be 10–12 weeks. A flow chart is included to give an overview of the study design and the main procedures that subjects will undergo in the course of both trials (figure 1: BASE-TRAIN trial; figure 2: BASE-ELECTRIC trial).

### Intervention

Study participants will be randomly assigned to either 3.2 g of sustained release BA (SR CarnoSyn) or identical looking placebo supplementation (both produced by Natural Alternatives International, San Marcos, USA) for a duration of 8–10 weeks. Patients, researchers and all PR staff, except the researchers performing randomisation and distributing the study supplements, will be blinded to treatment allocation.

The intervention will start directly from the onset (day 1) of the regular PR programme and will end after the last measurement of the study. Participants are instructed to coingest the supplements with meals, as this can beneficially influence muscle carnosine loading.31 As part of standard care, the total protein intake during the rehabilitation period will be set at 1.5–1.9 g of protein per kilogram of fat-free mass per day for all patients and a protein-rich supplement (±20 g of protein) is provided to every patient directly after training sessions. During breakfast and lunch, 2 tablets of BA/placebo (2×0.8 g) will be taken each time, resulting in a total daily intake of 3.2 g of BA/placebo. Furthermore, the participants will receive a personal diary, in which they keep track of intake of tablets and any possible side effects. With subjects’ self-reported compliance on tablet intake (diary) and returning of the pill containers, compliance with the intervention will be assessed. In addition, a moment will be scheduled every week in the context of patient safety to discuss possible side effects with the patient. The investigators will report all serious adverse events (SAEs) without undue delay after obtaining knowledge of the events to the sponsor.

### Table 1 Overview of the inclusion criteria for the two randomised controlled trials

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>BASE-TRAIN trial</th>
<th>BASE-ELECTRIC trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exercise modality</td>
<td>NLPE</td>
<td>NMES</td>
</tr>
<tr>
<td>Age</td>
<td>40–80 years</td>
<td>40–80 years</td>
</tr>
<tr>
<td>mMRC dyspnoea grade</td>
<td>≥2</td>
<td>≥3</td>
</tr>
<tr>
<td>No exacerbation/hospitalisation</td>
<td>&lt;4 weeks</td>
<td>&lt;4 weeks</td>
</tr>
<tr>
<td>Endurance time*</td>
<td>Not specified</td>
<td>100–300 s</td>
</tr>
<tr>
<td>Quadriceps strength</td>
<td>Not applicable</td>
<td>&lt;80% predicted</td>
</tr>
<tr>
<td>PR programme</td>
<td>Inpatient+Outpatient</td>
<td>Inpatient</td>
</tr>
</tbody>
</table>

*Endurance time is measured as walking endurance time (BASE-TRAIN) or cycle endurance time (BASE-ELECTRIC).

mMRC, modified Medical Research Council; NLPE, non-linear periodised exercise; NMES, neuromuscular electrical stimulation; PR, pulmonary rehabilitation; s, seconds.

**References**

who will report the SAEs to the accredited METC (CMO Regio Arnhem-Nijmegen).

Training protocols

In the BASE-TRAIN trial, NLPE training is applied to the patients. Periodisation is an essential organisational strategy and a cardinal principal of exercise training.5 33 34 Periodisation involves a division in distinct and smaller, more easy manageable but interrelated phases.34 The goals of these distinct phases contribute to the overall training plan. NLPE is featured by a frequent manipulation of training intensity, duration and repetition-volume. Exercise protocols are ultimately adapted based on September 23, 2023 by guest. Protected by copyright.http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2020-038836 on 13 September 2020. Downloaded from http://bmjopen.bmj.com/ on September 23, 2023 by guest. Protected by copyright.
on information emerging from the training sessions (eg, dyspnoea, residual fatigue, percutaneous oxygen desaturation, exertion of heaviness, pain). The programme is started with a preplanned NLPE protocol in which the patients receive three training sessions of 1–1.5 hours per week. The training plan and division in phases is shown in the online supplement (online supplemental file 1). As mentioned, individual protocol adaptions are possible, based on patients’ responses during training (eg, cause of exercise intolerance, response to a particular protocol). Whole-body exercise and resistance training are combined in each training session, and training parameters as frequency, intensity, duration and number of repetitions are monitored. The endurance training will be performed on a treadmill and the strength training will primary be performed on the leg press (lower extremity) and chest press and pull down (upper extremity). Furthermore, category-ratio Borg scores of leg fatigue and dyspnoea are reported immediately following exercise completion to evaluate exercise-induced breathlessness and fatigue.

In the BASE-ELECTRIC trial, NMES, being the primary exercise modality, is applied to the patients. During NMES, quadriceps and calf muscles of both legs will be simultaneously stimulated with a portable battery-operated electrical stimulator, using eight carbon-rubber electrodes (Tensmed S84, Enraf-Nonius, Rotterdam, The Netherlands). The stimulation protocol will consist of a symmetrical biphasic square pulse at 75 Hz (high-frequency NMES), a total duty cycle of 16s and a pulse time of 400 μs during a directly supervised session lasting 21 min in total. This high-frequency NMES has shown before to be safe, feasible and efficacious in dyspnoic and weakened patients with COPD. Patients will be specifically encouraged to increase current intensity at their will according to tolerance in each training session. The contraction time will be 6s with 8s relaxation excluding 1s ramp-up and 1s ramp-down. A total of eight carbon-rubber electrodes in moistened sponges are placed on the target muscles (four electrodes on each leg): two pairs of 8×12 cm on the quadriceps muscles and two pairs of 4×6 cm on the calf muscles. The electrodes on the quadriceps muscles are placed transversally 5–10 cm distal to the inguinal fold and 4–8 cm proximal to the patella. The electrodes on the calf muscles are placed longitudinally on the belly of the gastrocnemius muscles (protocol in accordance with study NL30155.068.09/MEC 09-3-072).

Study procedure
Patients will be informed about the trials by their treating chest physician during the evaluation of their baseline assessment. If patients are eligible and show interest in the study, they will receive the patient information letter. Participation will be verified through a phone call at least 1 week later. At the start of the study-related appointment, written informed consent will be obtained and participants will be randomised to either the experimental or the placebo group using a web-based generated randomisation programme. Randomisation will be stratified for gender in both trials and for one or two baseline endurance shuttle walk tests (ESWT) in the BASE-TRAIN trial. This will be explained in more detail in the Primary outcome section.

Participants will be randomised in a 1:1 ratio to BA (SR Carnosyn) or placebo. Allocation to treatment will be concealed. Randomisation and allocation (sealed opaque envelopes) will be performed by independent researchers not related to the current studies. These persons are neither participating in clinical treatment nor processing the study data. At the start of their PR programme, participants will receive a container with the intervention supplements. The containers will be provided with a blinded label, ensuring that the researchers, the PR staff and the participant will not be able to see which intervention supplement is taken. After inclusion, the participant’s general practitioner and chest physician will be informed about study participation.

Outcomes

Primary outcome
The primary outcome in both studies is exercise tolerance, a functional outcome that is measured as walking endurance time (BASE-TRAIN trial) or cycle endurance time (BASE-ELECTRIC trial). Walking endurance will be assessed via the ESWT, a standardised externally controlled constant paced field test at 85% of the predetermined maximal velocity (evaluated by the incremental shuttle walk test (ISWT)) until exhaustion. The preferred ESWT duration in this study is below 10 min, which has multiple reasons. First of all, this allows enough room for an additional improvement due to BA supplementation on pulmonary rehabilitation (MID: 174–279 s). Second, because of the hyperbolic power–duration relationship of the constant-load test, the interindividually preintervention ESWT time should be as much homogeneous as possible to better interpret intervention efficacy. At last, BA supplementation is proven to be most effective in exercise durations between 0.5 and 10 min. Therefore, patients with an ESWT >10 min perform the ESWT again at a higher speed.

Cycle endurance time will be determined with the constant work-rate cycle test (CWRT), performed on an ergometer at 75% of the maximal work rate (Wmax; determined by a cardiopulmonary exercise test (CPET) performed on a separate day during assessment) to volitional exhaustion (with a maximum of 20 min).

Secondary outcomes
Besides the CPET (both trials) and the ISWT (only in the BASE-TRAIN trial) is the exercise capacity measured with the 6 min walking test (6MWT) in the BASE-ELECTRIC trial and will be performed twice at baseline. Isometric and isokinetic quadriceps strength and endurance will be assessed using a computerised dynamometer (Biodex System 4 Pro, Biodex Medical Systems, New York, USA). Isometric quadriceps strength will be determined by three
maximal unilateral isometric knee extensions for 5 s at a knee angle of 60°, interspersed with 15 s of rest and will be defined as highest peak torque (newton-metre, Nm). Furthermore, participants will perform 30 sequential volitional maximal contractions at an angular velocity of 90° per second, while seated upright and the hip joint in 90° of flexion. Isokinetic quadriceps muscle strength will be defined as the highest peak torque (Nm). The isokinetic quadriceps muscle endurance will be defined as the total amount of delivered work (joules) during the set of 30 repetitions. 46 Maximal dynamic isotonic strength, to determine maximal quadriceps strength (leg press), will be assessed by one-repetition maximum using standard (fitness) equipment. 47

Body composition is measured by bioelectrical impedance analysis 48 (BASE-TRAIN trial) or dual-energy X-ray absorptiometry 49 (BASE-ELECTRIC trial). Physical activity will be measured using activity monitors (BASE-TRAIN: MoveMonitor; BASE-ELECTRIC: Actigraph GT9X), which provide simple, valid and reliable measures of physical activity in patients with COPD. 50 The Short Physical Performance Battery test is designed to measure functional status and physical performance 41 and will be carried out in the BASE-ELECTRIC trial.

Vastus lateralis muscle biopsies will be performed by an experienced physician during two study-related appointments (pre-rehabilitation, at least 1 week before the start of the PR programme; and post-rehabilitation) using standard aseptic technique and local anaesthesia. A side cutting needle muscle biopsy will be passed through an incision to obtain approximately 100 mg of muscle tissue. 52, 53 Muscle components of carnosine metabolism (eg, BA, carnosine, taurine and histidine) will be quantified by means of reserved-phase high-performance liquid chromatography. 54 Muscle oxidative stress and inflammation will be assessed via immunoblotting and specific activity kits. 55, 56 Fasting venous blood will be assessed for the analysis of systemic components of carnosine metabolism as well as systematic markers of oxidative stress and inflammation at rest.

Two domains of cognitive function 57 will be evaluated: executive functioning will be assessed using the M-WCST and divided attention will be examined via the SCWT 58, 59 Lung inflammatory and oxidative stress biomarkers will be measured (only in the BASE-ELECTRIC trial) using VOCs 60 and FeNO. 61

The severity of dyspnoea is measured via the modified Medical Research Council dyspnoea scale. 62 Health-related quality of life will be assessed using the COPD Assessment Test. 63 The Hospital Anxiety and Depression Scale will be used as a screening tool to detect clinical signs of anxiety and depression. 64, 65 Fatigue severity will be measured by the subjective fatigue subscale of the Checklist Individual Strength (CIS-Fatigue). 66 Problematic activities of daily life will be measured (only in BASE-ELECTRIC study) using the Canadian Occupational Performance Measure. 67 At last, the subjects’ compliance on tablet intake, patient safety and possible side effects are assessed as secondary outcome measures as described in the Intervention section.

Other outcomes
Additional outcomes are used to characterise patients at baseline. Pulmonary function will be assessed using post-bronchodilator spirometry, whole-body plethysmography and diffusion capacity according to the ATS/ERS guidelines for pulmonary function testing. 68-70 Furthermore, respiratory muscle strength, using maximal inspiratory pressure and maximal expiratory pressure measurements, will be determined. 71 An arterial blood sample is collected to determine arterial blood gases at rest. 72 Additionally, patient characteristics as age, gender, level of education, marital status, smoking status, exacerbation/hospitalisation frequency and medical history (Charlson Comorbidity Index), 73 medication and/or oxygen use will be assessed at baseline during an intake interview.

Table 2 provides an overview of the measurements performed during the several time points of the studies.

Sample size calculation
Since no preliminary data are available concerning the effects of BA supplementation combined with exercise training on exercise tolerance (walking or cycle endurance time) in an elderly population (with or without chronic disease), a more conservative approach based on the minimal clinical important differences (MCID) of the walking and cycle endurance time, in COPD patients treated in PR, is used.

In the BASE-TRAIN trial, a total of 154 patients is needed to detect a MCID of 177 s 40, 74 in walking endurance time with an estimated drop-out rate of 10%, based on recent local unpublished data (α=0.05; β=0.80). In the BASE-ELECTRIC trial, a total of 68 patients is needed to detect a MCID of 105 s 75 in cycle endurance time with an estimated dropout rate of 25%, based on the study of Sillen et al (α=0.05; β=0.90). 4

Furthermore, a sample size calculation for the required muscle biopsies is included. Based on the unpublished findings of De Brandt et al (NCT02770417; effect size: 1.39), a group size of n=15 is required for each group in each trial, including an estimated dropout rate of 25% (α=0.05; β=0.90). Therefore, the aim will be to perform muscle biopsies in 30 patients with COPD (15 for the BA group and 15 for the placebo group) in each trial.

Data management and statistical analyses
In order to minimise missing data, only essential information will be collected at each visit, user-friendly case-report forms have been developed, and the majority of the tests and questionnaires will be performed in the presence of a researcher. The study variables will be tested for normality. For all data, point measures and measures of variability will be provided. Demographic variables (such as age, sex, educational level, smoking history) will be compared between patients in the BA and placebo group, using unpaired t-test or Mann-Whitney U
<table>
<thead>
<tr>
<th>Table 2</th>
<th>Overview outcome measurements</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline assessment</td>
</tr>
<tr>
<td>Patient characteristics</td>
<td>Demographics, including age, gender, marital status</td>
</tr>
<tr>
<td></td>
<td>Medical history: Charlson Comorbidity Index</td>
</tr>
<tr>
<td></td>
<td>COPD history: number of exacerbations and hospital admissions</td>
</tr>
<tr>
<td></td>
<td>Smoking history and behaviour</td>
</tr>
<tr>
<td></td>
<td>Current medication</td>
</tr>
<tr>
<td></td>
<td>Use of long-term oxygen therapy</td>
</tr>
<tr>
<td>Safety reporting</td>
<td>Exacerbations</td>
</tr>
<tr>
<td></td>
<td>Hospitalisations</td>
</tr>
<tr>
<td></td>
<td>Side effects</td>
</tr>
<tr>
<td>Exercise capacity and exercise tolerance</td>
<td>Cardiopulmonary exercise test</td>
</tr>
<tr>
<td></td>
<td>Constant work rate cycle test</td>
</tr>
<tr>
<td></td>
<td>Incremental shuttle walk test</td>
</tr>
<tr>
<td></td>
<td>Endurance shuttle walk test</td>
</tr>
<tr>
<td></td>
<td>6 min walk test</td>
</tr>
<tr>
<td>Body composition</td>
<td>Body mass index</td>
</tr>
<tr>
<td></td>
<td>Bioelectrical impedance analysis</td>
</tr>
<tr>
<td></td>
<td>Dual-energy X-ray absorptiometry scan</td>
</tr>
<tr>
<td>Muscle function</td>
<td>Quadriceps muscle strength (computerised dynamometer)</td>
</tr>
<tr>
<td></td>
<td>Quadriceps muscle endurance (computerised dynamometer)</td>
</tr>
<tr>
<td></td>
<td>One-repetition maximum</td>
</tr>
<tr>
<td>Muscle characteristics (muscle biopsy)</td>
<td>Components of carnosine metabolism</td>
</tr>
<tr>
<td></td>
<td>Muscle inflammation</td>
</tr>
<tr>
<td></td>
<td>Muscle oxidative stress</td>
</tr>
<tr>
<td>Pulmonary function</td>
<td>Spirometry/flow volume</td>
</tr>
<tr>
<td></td>
<td>Whole-body plethysmography</td>
</tr>
<tr>
<td></td>
<td>Diffusion capacity</td>
</tr>
<tr>
<td></td>
<td>Maximal inspiratory and expiratory pressure</td>
</tr>
<tr>
<td></td>
<td>Arterial blood gases, including PaO₂ and PaCO₂</td>
</tr>
<tr>
<td>Systemic factors</td>
<td>Systemic components of carnosine metabolism</td>
</tr>
<tr>
<td></td>
<td>Systemic markers of oxidative stress</td>
</tr>
<tr>
<td></td>
<td>Systemic markers of inflammation</td>
</tr>
<tr>
<td>Physical activity</td>
<td>MoveMonitor/Actigraph measurement</td>
</tr>
<tr>
<td>Questionnaires</td>
<td>Dyspnoea: Modified Medical Research Council</td>
</tr>
<tr>
<td></td>
<td>Health-related quality of life: COPD Assessment Test</td>
</tr>
</tbody>
</table>

Continued
test, as appropriate, for continuous variables and $\chi^2$ tests for categorical variables.

To evaluate the changes in exercise tolerance, lower-limb muscle function, muscle carnosine, muscle and systemic BA, taurine and histidine, muscle, systemic and pulmonary markers for inflammation and oxidative stress and cognitive function, a 2×2 general linear model repeated measures analysis of variance (ANOVA) will be performed, with ‘supplementation group’ (BA, PL) as between-subjects factor and ‘time’ (PRE vs POST) as a within-subjects factor. If, however, the assumptions of repeated measures ANOVA are not met, POST–PRE deltas ($\Delta$) will be calculated, and exercise tolerance changes between groups will be analysed using an unpaired t-test (non-parametrical alternative: Mann-Whitney U test). Differences in changes ($\Delta$) in quality of life, dyspnoea, symptoms of anxiety and depression, problematic activities of daily life and fatigue between groups will be analysed using an unpaired t-test when the data are normally distributed. For skewed data, the Mann-Whitney U test will be performed. Pearson’s or Spearman’s correlation will be calculated between baseline muscle carnosine content and absolute increase in muscle BA/carnosine. Furthermore, correlations will be conducted between relative changes in muscle BA/carnosine content and performance parameters. To counteract the problem of multiple comparisons, the Bonferroni correction will be used. All statistical analyses will be performed using Statistical Package for the Social Sciences (SPSS) v. 25.0. A priori, a two-tailed p value of ≤0.05 is considered as significant.

**Patient and public involvement**

Members of the CIRO client council and patient representatives from Lung Foundation Netherlands are active members of the BASES consortium and have been involved in setting up the grant proposal, in reviewing both study designs (particularly the patient informed consent) before submission for ethical approval and in discussing the outcomes assessment. Moreover, this patient advisory board will provide unprecedented insight into improving study feasibility, recruitment and retention, and in understanding patient perceptions and receptivity to current approaches, new practices and possible future (combinations of) therapies. The patient advisory board will also be included in the development of post-trial communication.

**Ethics and dissemination**

The studies will be conducted according to the guidelines of the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013)76 and in accordance with the Medical Research Involving Human Subjects Act (WMO). Written informed consent will be obtained from all participants (particularly the patient informed consent) before submission for ethical approval and in discussing the outcomes assessment. Moreover, this patient advisory board will provide unprecedented insight into improving study feasibility, recruitment and retention, and in understanding patient perceptions and receptivity to current approaches, new practices and possible future (combinations of) therapies. The patient advisory board will also be included in the development of post-trial communication.
DISCUSSION

Strengths
To date, most studies that examined the effects of BA supplementation have focused on improving exercise tolerance in athletes. However, results of BA supplementation in the elderly population suggest that there is rationale for further research in this area. To the best of our knowledge, our planned studies will be the first in which BA supplementation is combined with a supervised exercise intervention in patients with COPD. A major strength of the present studies is the fact that these are methodologically rigorous randomised controlled trials using a computer-generated randomisation scheme and strict allocation concealment with accurate sample size calculation. This will provide a valid indication of the effectiveness of BA supplementation in patients with COPD receiving PR. In addition, the use of a responsive outcome measure for exercise tolerance will increase the likelihood of being able to assess whether there are any benefits in adding BA supplementation to PR in patients with COPD. In the current studies, we specifically focus on patients with COPD with explicit functional limitations and high symptom burden attending PR. The strict inclusion criteria are another strength of both trials, as patients with severe COPD are expected to benefit the most from BA supplementation.

Furthermore, we optimised both the dosage and the duration of supplementation in order to increase the muscle carnosine response to BA supplementation. In addition, 3.2g of BA per day for a duration of 8–10 weeks will result in a cumulative dose of 179–224g of BA, which will lead to significantly augmented muscle carnosine concentrations (>40%). The protocols also embody other factors that can lead to greater muscle carnosine gains, such as supplement formulation (slow-release formula), ingestion timing in relation to meals (coingestion with breakfast and lunch) and exercise (NLPE or NMES training programme as part of PR). Moreover, the trials examine the mechanism of carnosine loading in a diseased population by analysing levels of muscle carnosine concentrations from BA supplementation. This way, we aim to identify relevant factors that explain variances in muscle carnosine loading and try to elucidate carnosine’s role as a potential antioxidant. And last, the structure of the BASES consortium, including a patient advisory board, a core project team and a steering committee, allows us to enhance the research capacity, to share (academic) resources, to disseminate study results and to accelerate future research.

Methodological considerations
First, limited funding makes it difficult to set up long-term follow-up, although analysing the sustainability of outcomes would certainly be worthwhile. As such, long-term benefits will not be investigated. Second, despite our efforts to increase compliance through inpatient follow-up during the PR programme, adherence to the prescribed supplementation protocol is only monitored by asking participants about their intake using a diary and by documenting the remaining tablets at the end of the supplementation period. Therefore, it is possible that the actual compliance is different and forgotten tablets are discarded. However, this is comparable with daily practice as patients may behave in the same manner. Furthermore, the actual efficacy of BA supplementation is monitored by means of quantifying muscle carnosine levels through muscle biopsies of the vastus lateralis muscle.

Third, all patients start with a preplanned NLPE protocol in the BASE-TRAIN trial. However, individual protocol adaptions are possible based on patients’ responses during training as it is part of usual care. This might result in (minor) differences in exercise training programme between the BA and placebo group. As we deliver patient-tailored care with the purpose to generate an optimal result for each patient, which depends on the patient’s abilities, needs and goals and is therefore patient-specific, we will not be able to apply one single protocol to all patients. Moreover, training parameters as frequency, intensity, duration and number of repetitions will be closely monitored during the study. This will allow additional post hoc analyses to evaluate the effect of potential differences in exercise training programme that arise throughout the study. Furthermore, we acknowledge the fact that the protein-rich supplement, given after each training session as part of standard care, could potentially reduce the between-group difference regarding the primary outcome (exercise tolerance), since additional protein intake could enhance training benefits in the control group. In this way, however, the potential risk of a BA-induced decline in circulating and/or muscle histidine levels is minimised by additional intake of protein (post-training) in these patients with COPD.

Clinical implications
The BASE-TRAIN and BASE-ELECTRIC studies will examine whether and to what extent BA supplementation can augment the exercise tolerance outcomes of PR. Improving exercise tolerance is a major therapeutic goal in COPD and there are theoretical reasons for presuming that specific oral nutritional supplements may further enhance the outcomes of exercise training, an intervention that is of proven clinical benefit in patients with COPD. Furthermore, the present studies will gain insight in the characteristics of patients that do and do not benefit from BA supplementation and whether these benefits directly mirror changes in intracellular carnosine.

CONCLUSION
In conclusion, both exercise training and BA supplementation effectively increase exercise tolerance in several populations. The BASE-TRAIN and BASE-ELECTRIC trials will be the first to evaluate the effects of BA...
supplementation in addition to exercise training (either NLPE or NMES) in patients with COPD. In this article, the study rationale and protocols of both trials are described, and a preliminary analysis of the possible strengths and limitations is outlined.

Author affiliations
1Department of Research and Development, CIRO, Horn, The Netherlands
2NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands
3Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands
4Department of Pulmonary Diseases, Radboud UMC Dekkerswald, Nijmegen, The Netherlands
5Reval Rehabilitation Research, Biomedical Research Institute, Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium
6Department of Physiotherapy, CIRO, Horn, The Netherlands
7Department of Pulmonology, Merem Pulmonary Rehabilitation Centre, Hilversum, The Netherlands
8Department of Physiology, CIRO, Horn, The Netherlands
9Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, The Netherlands
10Patient Advisory Council, Lung Foundation Netherlands, Amersfoort, The Netherlands
11Client Council, CIRO, Horn, The Netherlands
12Department of Respiratory Medicine, CHU Sart-Tilman Liege, GIGA I3, Liege, Belgium
13PhyMedExp, INSERM – CNRS, University of Montpellier – Montpellier CHU, Montpellier, France
14Department of Movement and Sport Sciences, University Ghent, Ghent, Belgium

Twitter Jana de Brandt @JanaDeBrandt, Frits M E Franssen @fritsfranssen, Chris Burtin @burtin_chris, Wim Derave @TeamDerave and Martijn A Spruit @martspruit @ pulmonary_rehab

Contributors RM and AAFS are responsible for the recruitment, data collection and data analysis. MAS is the principal investigator of CIRO and BASES project leader. HWWH is the principal investigator of Radboud University Medical Centre. Together with FMEF, MJHS, EFMW, CB, JDB, PK, EBdV, BvdV, FNS, MH, PP, IE and WD, they form the BASES consortium and are responsible for the design, recruitment and interpretation of the results. JMO and JD are members of the patient advisory board. All authors contributed to the writing of this manuscript, read and approved the final version of the manuscript.

Funding The BASES project is supported by the Lung Foundation Netherlands (#5.1.18.232). The research of FWO Aspirant Jana De Brandt is supported by Research Foundation – Flanders (FWO grant #11B4718N). The research of FWO Aspirant Jana De Brandt is sponsored by Research Foundation – Flanders (FWO grant #11B4718N).

Competing interests FMEF reports research grants from AstraZeneca and Novartis, not related to the current projects, and personal fees for consultancies and lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and TEVA. EBdV reports personal fees for consultancies and lectures from Boehringer Ingelheim, Chiesi, Mylan, Novartis, Vivasol and TEVA, not related to the current projects, FNS reports speakers fees from AstraZeneca, Chiesi, Menarini, Mundipharma and Novartis, reports consultancy fees from GSK; and reports service on an advisory board for AstraZeneca, Chiesi, GSK and Novartis, all outside the submitted work. MH reports research grants from Bastide Medical, not related to the current project; personal fees from AstraZeneca for participation to scientific lectures; financial support for congress participation from SOS Oxygen, Eole Santé, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca; and hospitalities during local scientific meetings from ALK-Abelló, Actelion Pharmaceuticals France, Vifor Fresenius Medical Care Renal Pharma, Sanofi Aventis France, Novartis Pharma, ULV Medical Sud, Chiesi, SOS Oxygen Mediterranean. MAS reports a research grant from Netherlands Lung Foundation (grant number 5.1.18.232) for the described BASE-TRAIN and BASE-ELECTRIC study. Moreover, MAS reports other grants from Netherlands Lung Foundation, grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, and a grant from Stichting Astma Bestrijding, all outside the submitted work.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting or dissemination plans of this research. Refer to the Methods and analysis section for further details.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Roy Meys http://orcid.org/0000-0002-4855-530X
Jana de Brandt http://orcid.org/0000-0003-3463-1911
Martijn A Spruit http://orcid.org/0000-0003-3822-7430

REFERENCES


